Prof Olivier Lambotte speaks to ecancer about the management of adverse events associated to the use of immune-checkpoint inhibitors.

He outlines the types of toxicities commonly associated with these agents, including autoimmune and inflammatory manifestations.

Prof Lambotte also discusses the feasibility of resuming the use of these drugs in patients who have discontinued treatment due to adverse events.

He concludes by explaining how toxicities are managed across different subsets of patients and emphasises that it is crucial for every cancer centre to have a multi-disciplinary advisory board to ensure patients receive the best care when treated with these drugs.

This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.